Genentech: Positive Phase III Results for Inavolisib Combo in Breast Cancer

 

• Phase III (INAVO120) results shows that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line setting
• PIK3CA mutations, found in approximately 40% of HR-positive breast cancers, are linked to tumor growth, disease progression, and treatment resistance
• Data will be shared with health authorities and presented at an upcoming medical meeting

https://www.biospace.com/article/releases/genentech-announces-positive-phase-iii-results-for-inavolisib-combination-in-people-with-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation/